TCMP
AMGN icon

Thrive Capital Management (Pennsylvania)’s Amgen AMGN Stock Holding History

Thrive Capital Management (Pennsylvania)’s Portfolio AMGN Stock Details AMGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.58M Sell
4,490
-136
-3% -$48.5K 0.35% 91
2025
Q4 		$1.51M Sell
4,626
-814
-15% -$258K 0.34% 91
2025
Q3 		$1.54M Sell
5,440
-1,367
-20% -$396K 0.4% 87
2025
Q2 		$1.9M Buy
6,807
+6,016
+761% +$1.7M 0.6% 73
2025
Q1 		$247K Buy
+791
New +$234K 0.15% 105
2024
Q4 		– Sell
-878
Closed -$283K – 100
2024
Q3 		$283K Sell
878
-235
-21% -$76.9K 0.13% 157
2024
Q2 		$348K Sell
1,113
-3,421
-75% -$1.01M 0.16% 149
2024
Q1 		$1.29M Buy
4,534
+3,333
+278% +$975K 0.69% 24
2023
Q4 		$346K Sell
1,201
-808
-40% -$220K 0.19% 88
2023
Q3 		$540K Buy
2,009
+91
+5% +$22.7K 0.3% 54
2023
Q2 		$426K Buy
1,918
+686
+56% +$159K 0.24% 70
2023
Q1 		$298K Buy
1,232
+388
+46% +$95.2K 0.19% 90
2022
Q4 		$222K Sell
844
-835
-50% -$224K 0.15% 108
2022
Q3 		$378K Buy
+1,679
New +$407K 0.26% 70

Other funds holding AMGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Thrive Capital Management (Pennsylvania)'s AMGN Position: Q1 2026 in Review

Thrive Capital Management (Pennsylvania) reduced its Amgen (AMGN) stake by 2.9% in Q1 2026, selling an estimated $48.5K and leaving 4,490 shares worth $1.58M. The position accounts for 0.35% of the portfolio, ranked #91.

Thrive Capital Management (Pennsylvania) first reported a position in AMGN in Q3 2022 and has held it in 14 quarters since. The position peaked at $1.9M in Q2 2025. 3,131 funds tracked by Wall St. Rank hold AMGN as of Q1 2026.

  • Thrive Capital Management (Pennsylvania) held 4,490 shares of Amgen worth $1.58M as of Q1 2026.
  • Thrive Capital Management (Pennsylvania) sold 136 Amgen shares in Q1 2026, an estimated $48.5K.
  • Amgen made up 0.35% of Thrive Capital Management (Pennsylvania)'s portfolio in Q1 2026, its #91 holding.
  • Thrive Capital Management (Pennsylvania) first reported a position in Amgen in Q3 2022 and has held it in 14 quarters since.
  • Thrive Capital Management (Pennsylvania)'s Amgen position peaked at $1.9M in Q2 2025.
  • 3,131 funds tracked by Wall St. Rank held Amgen as of Q1 2026.

Based on Thrive Capital Management (Pennsylvania)'s 13F filing for Q1 2026, filed 27 Apr 2026.